Open AccessCrohn’s Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab
Author(s) -
Aasem Abu Shtaya,
Shai Cohen,
Yana Kogan,
Michal Shteinberg,
Ori Sagool
Publication year - 2021
Publication title -
european journal of case reports in internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2284-2594
DOI - 10.12890/2021_002265
Subject(s) - medicine , vedolizumab , disease , crohn's disease , inflammatory bowel disease , exacerbation , subclinical infection , ulcerative colitis , complication , calprotectin
Crohn’s disease is a chronic inflammatory bowel disease that can affect any part of the GI tract, which is frequently associated with extra-intestinal manifestations. Pulmonary parenchymal disease is very uncommon and usually considered to be debilitating and harder to diagnose. Pulmonary granulomas are rarely described in the literature as a complication of Crohn’s disease. Here, we present a patient with Crohn’s disease exacerbation who developed granulomatous lung disease under treatment with vedolizumab. Our case may add evidence to the emerging theory that gut-selective biologic agents could lead to upregulation of some pro-inflammatory factors leading to the evolution of pulmonary disease.